Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of total asiaticoside and its correlative components in medicament for preventing and/or treating leucoderma

A technology of total asiaticoside and asiaticoside is applied in the directions of medical preparations containing active ingredients, plant/algae/fungus/moss ingredients, pharmaceutical formulations, etc. Adverse reactions are common and other problems, to achieve unique curative effect, good antioxidant effect

Inactive Publication Date: 2013-04-17
SHANGHAI SHYNDEC PHARMA CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although western medicine treatment is simple, surgery is often used, but due to the frequent adverse reactions or complete recovery is difficult; some patients use traditional therapy, although the time is long, but the adverse reactions of drugs are few

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Asiaticoside cream ointment (calculated asiaticoside, 10 g: 0.25 g) and asiaticoside gel (calculated asiaticoside, 10 g: 0.25 g) were prepared according to the common method in pharmacy.

[0022] (1) Preparation of guinea pig vitiligo model by chemical depigmentation agent

[0023] Preparation of vitiligo animal model: take 70 guinea pigs with black or black flower hair (black skin), and use sodium sulfide to remove the black hair on the back of about 4×4cm 2 . were randomly divided into 7 groups,

[0024] (1) Normal control group: excipients

[0025] (2) Model control group: excipients

[0026] (3) Positive drug control group:

[0027] (4) Higher 1-dose group (1 time of the middle-dose group):

[0028] (5) Drug high 2 dose group (1 / 2 times of middle dose group):

[0029] (6) Medium-dose drug group:

[0030] (7) Low-dose drug group:

[0031] Use 8% sodium sulfide for hair removal, once every 4 days. Except for the normal group, apply distilled water, and the oth...

Embodiment 2

[0034] Prepare asiaticoside, asiaticoside, madecassoside and asiaticoside B solutions.

[0035] (1) The migration and adhesion of the medicine of the present invention to epidermal melanocytes in vitro

[0036] Passage (second generation) human epidermal melanocytes were counted and inoculated in culture flasks to ensure that the number of cells in each flask was the same. The drug test concentrations were 10, 50, 100, 150, 200 μg / ml, and the blank control group, and cultured for 3 days.

[0037] The sodium hydroxide lysis method was used to measure the melanin content and the melanocyte proliferation rate, and the microporous membrane method was used to measure the cell migration and the melanocyte migration rate.

[0038] The test results show that the drug of the present invention has little effect on the proliferation of melanocytes, but it has a certain difference in the migration rate of melanocytes compared with the control group. There was no significant difference wh...

Embodiment 3

[0043] According to the common method of pharmacy, the medicine of the present invention is prepared into a common external preparation ointment. The ointment in this example uses asiaticoside, asiaticoside, madecassoside and asiaticoside B as medicinal ingredients.

[0044] Screen the generalized progressive vitiligo case, select three positions at random (select exposure or non-exposure position simultaneously), adopt random, controlled, double-blind method to carry out the clinical observation of 60 cases, use respectively asiaticoside ointment of the present invention, product Madecassoside ointment, madecassoside ointment and asiaticoside B ointment, hormone and matrix control were observed once every 2 weeks on average, and photographed each time for a total of 3 months.

[0045] Efficacy criteria: recovery: skin lesions completely subsided. Significantly effective: the white spots subside or shrink, and the area of ​​normal skin color is more than 50% of the original s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of application of centella asiatica extract. The total asiaticoside or asiaticoside, hydroxy asiaticoside, asiaticoside B in the invention has unique efficacy on treating leucoderma, has good immunosuppression effect, can promote repairing, proliferation, and migration of melanocytes, and is related to the effect of melanin metabolic regulation systems such as cytokines of melanocyte stimulating hormone, keratinocyte, and the like. The new leucoderma medicament provided in the invention has unique efficacy on treating leucoderma, can control or heal conditions of patients with leucoderma.

Description

technical field [0001] The invention relates to the application of asiaticosides and related components in the field of pharmacy. Background technique [0002] Vitiligo (vitiligo) is a common primary, localized or generalized depigmentation skin disease, which is caused by the dysfunction and loss of the tyrosinase system in the melanocytes of the skin and hair follicles. The above is mainly manifested as the reduction or disappearance of melanocytes. [0003] The incidence of vitiligo varies with regions and races. Generally, people with lighter skin have a higher incidence rate, such as 0.38% for Danes, about 1% for whites in the United States, and the incidence rate for yellow people is between whites and blacks. Among races, the domestic prevalence rate is 0.09%-2.7%. Tens of millions of sick people. Affected by genetic factors, the age of onset of most patients is less than 30 years old, and there is no significant difference between men and women. Vitiligo damage c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/23A61P17/00
Inventor 杨国红王曙光杨婷婷陈解春林梦感
Owner SHANGHAI SHYNDEC PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com